相关实验视频

Updated: Jun 7, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

使用循环瘤DNA来预测肺癌免疫疗法疗效的机遇和挑战

Shanshan Li^1,2, Ting Yuan², Jing Yuan³

¹School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, 400054, China.

Journal of cancer research and clinical oncology

|November 15, 2024

概括

循环瘤DNA (ctDNA) 显示出作为预测肺癌患者对免疫检查点抑制剂 (ICI) 反应的生物标志物具有前途. 需要进一步的研究来克服挑战,并将ctDNA分析完全整合到临床实践中.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子诊断学分子诊断学

背景情况:

免疫检查点抑制剂 (ICI),特别是抗PD-1/PD-L1抗体,已经在肺癌治疗中取得了进步.
肺癌中ICI的响应率仍然有限,需要改进预测生物标志物.

研究的目的:

审查正在接受免疫治疗的肺癌患者循环瘤DNA (ctDNA) 分析的当前数据.
确定挑战,并讨论ctDNA在肺癌免疫治疗中的临床应用的未来研究方向.

主要方法:

对肺癌免疫治疗中ctDNA分析现有研究的综述.
分析ctDNA在ICI反应的诊断,表征,监测,预后和预测中的作用.

主要成果:

ctDNA分析提供了对肺癌的最小侵入性监测和表征.
预处理ctDNA可以检测残留疾病并评估瘤负担,而早期ctDNA动态可以预测结果并区分伪进展.
ctDNA可以识别ICI反应的遗传预测因子.

结论:

ctDNA具有作为肺癌免疫治疗的预后和预测生物标志物的巨大潜力.
对ctDNA分析临床应用的障碍仍然存在,需要进一步调查和解决.

关键词:

循环瘤DNA是循环中的瘤DNA.免疫检查点抑制剂免疫检查点抑制剂肺癌是一种肺癌.突变突变是一种突变.bTMBB 这是一个很好的选择.

更多相关视频

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.